Form 4: Georges Gemayel Reports Stock Transactions in Supernus Pharmaceuticals

Director Georges Gemayel reports acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 22, 2025.

Summary

• On February 22, 2025, Georges Gemayel, a director of Supernus Pharmaceuticals, reported transactions involving the company's stock.
• Gemayel acquired 5,369 shares of common stock.
• Simultaneously, Gemayel disposed of 5,369 restricted stock units, which were settled in common stock upon vesting on the same date.
• Following these transactions, Gemayel beneficially owns 18,684 shares of Supernus Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These filings provide transparency into the trading activities of company insiders and can be monitored by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• It can influence investor sentiment depending on the perceived implications of the insider's trading activity.

Key Dates

Keywords

Supernus Pharmaceuticals, Georges Gemayel, stock transaction, Form 4, beneficial ownership, restricted stock units, common stock, director